Longevity Roundtable: Rapamycin, Reprogramming, Peptides & Proactive Healthcare

What does proactive healthcare actually look like in 2026? I sit down with Dr. Brian Kennedy and Dr. Marcus Ranney to explore the current state of longevity medicine — separating real science from hype, and discussing where the field may be heading next. In this wide-ranging discussion we dive into; What proactive healthcare really meansWhy lifestyle still forms the foundation of healthspanWhich biomarkers and diagnostics matter mostThe promise and limitations of biological age clocks like LineageEthical questions around off-label prescribing in longevity medicineGLP-1 drugs, SGLT2 inhibitors, thyroid optimization, and proactive use of pharmaceuticalsThe growing peptide landscape and the dangers of counterfeit productsWhy we urgently need better clinical trials for longevity interventionsBrad Stanfield’s new rapamycin trial and what the results may (and may not) meanThe future of epigenetic reprogramming and whether “reversing aging” could someday alter behavior or personality itselfThis was a particularly nuanced and intellectually honest conversation. Brian and Marcus both bring different perspectives, but we all agree on one thing: the field needs more rigorous data, more transparency, and more thoughtful discussion.Whether you’re deeply immersed in longevity science or just trying to better understand the rapidly evolving world of healthspan medicine, I think you’ll enjoy this one.